Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. — ImportanceAmyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy....

Evidence span

Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. — ImportanceAmyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy....

From Zimmer JA et al. 2025, JAMA neurology

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Aged; Aged, 80 and over; Middle Aged — JAMA neurology 2025 (cited ≥50×)

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required